FDA Inspections Still Lag Behind Pre-Pandemic Levels, Raising Drug Safety Concerns

The FDA’s drug manufacturer inspections have not yet returned to pre-pandemic levels, raising concerns about drug safety and regulatory compliance. The Government Accountability Office highlights the need for enhanced inspection capabilities and workforce retention to ensure the safety of medications. As the agency navigates post-pandemic challenges, prioritizing foreign inspections is crucial for public health.